Responder Hf
Posted Date: Mar 5, 2025
- Investigator: Jennifer Cook
- Specialties:
- Type of Study: Device
The primary objective of this double-blind, sham-controlled, clinical trial is to further evaluate the clinical efficacy of the Corvia Atrial Shunt in symptomatic heart failure patients with a left ventricular ejection fraction (LVEF) = 40%, and elevated left sided filling pressures. The implant is placed across the interatrial septum percutaneously in the cardiac catheterization laboratory (i.e. no surgery needed). In the setting of elevated left atrial pressure greater than right atrial pressure, the implant allows left-to-right blood flow. The Corvia Atrial Shunt System has a proven mechanistic effect of reducing pulmonary capillary wedge pressure (PCWP) during exercise and, in a series of clinical studies with up to three years of follow-up, was demonstrated to remain patent, relieve symptoms, improve quality of life and reduce heart failure hospitalizations without raising safety concerns.
Criteria:
Null
Keywords:
Interatrial Shunt For Symptomatic Hfpef
For More Information:
Elias Shamieh
513-558-3016
shamiees@ucmail.uc.edu